NHS cleared to use Astellas' non-hormonal menopause drug Around half a million women in England will soon be able to access Astellas' non-hormonal Veoza treatment for symptoms associated with menopause.

Around half a million #women in #England will soon be able to access a non-hormonal treatment for #hotflushes associated with #menopause, after #Astellas' Veoza was cleared for #NHS use.

pharmaphorum.com/news/nhs-cle...

Biopharma Partnership: Astellas and Vir Bio Collaborate on Precision Oncology - AktieGo Astellas Pharma and Vir Biotechnology just announced a global strategic collaboration. The deal centers on VIR-5500, an investigational T-cell engager (TCE) for prostate cancer. I’m looking at the fin...

Astellas and Vir Biotechnology partner on a $1.7B deal to fight prostate cancer. New ""masked"" T-cell tech is the focus.

#Oncology #bir #biotechnology #aktiego #HealthNews #Astellas

aktiego.com/sectors/biot...

Astellas bets on Vir cancer drug, and other licensing deals Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

#pharmalicensingdeals #pharmaceuticalassets #VirBiotech #Vir #HarbourBioMed #UnnaturalProducts #Genhouse #CSL #Astellas #SolsticeOncology #antiCTLA4antibody #Novartis #UnnaturalProducts #macrocyclicpeptidedrugs #GileadSciences #syntheticlethality #GenhouseBio #Arcellx #EliLilly
zurl.co/HOdjt

アステラス、ミラベグロンの米国特許訴訟でLupinと和解──訴訟終結、条件は非開示 | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

Astellas reaches settlement with Lupin in U.S. mirabegron patent litigation

stellanews.life/technology/8...

AI impact rating（reference only）: ★★☆☆☆
This is an experimental indicator and not a guarantee of accuracy.

#Astellas #Mirabegron #Myrbetriq #PatentLitigation #Settlement #PharmaIndustry

アステラス、日本第3相STARLIGHT 2でVMS有意改善──フェゾリネタントが主要評価項目達成、承認申請へ | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

Astellas reports positive Phase 3 STARLIGHT 2 results in Japan for fezolinetant in vasomotor symptoms

stellanews.life/technology/8...

#Menopause #VMS #Fezolinetant #Phase3 #Astellas

Zydus follows Lupin with Myrbetriq settlement deal Zydus has joined Lupin in agreeing to settle patent litigation with Astellas on its generic of big-selling overactive bladder drug Myrbetriq.

#ZydusLifesciences has reached a #settlement agreement with #Astellas in a #patentdispute involving #overactivebladder therapy Myrbetriq, which will allow its #generic to remain on sale in the US.

Pharma has varying levels of success developing drugs. That's a boon for biotech

Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022

$AMGN, $NVO, #Eisai top the list
$GSK, #Astellas, $ABBV are at the bottom

#learnbiotechinvesting #BiotechPrometheus

Exploratory Analyses Show Enhanced Outcomes with VYLOY Plus Chemotherapy in Cancer Care Management Recent analyses reveal significant survival advantages for patients undergoing VYLOY alongside chemotherapy when adverse events are properly managed, indicating vital steps in cancer treatment.

Exploratory Analyses Show Enhanced Outcomes with VYLOY Plus Chemotherapy in Cancer Care Management #USA #Northbrook #Astellas #VYLOY #zolbetuximab

Pharma has varying levels of success developing drugs. That's a boon for biotech

Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022

$AMGN, $NVO, #Eisai top the list
$GSK, #Astellas, $ABBV are at the bottom

#learnbiotechinvesting #BiotechPrometheus

Astellas to Share Promising New Data on GI Cancers at 2026 ASCO Symposium Astellas Pharma will unveil significant data on potential treatments for gastrointestinal cancers at the ASCO GI Cancers Symposium in January 2026.

Astellas to Share Promising New Data on GI Cancers at 2026 ASCO Symposium #Japan #Tokyo #Astellas #zolbetuximab #ASP3082

The #EMA has started a review of a regimen based on #Pfizer and #Astellas' Padcev and #MSD's Keytruda that has been described as a game-changer in the treatment of muscle-invasive #bladdercancer (MIBC).

buff.ly/h9f0kfX

FDAが筋層浸潤性膀胱がんに対するパドセブ＋キイトルーダの周術期併用療法を承認、EV-303試験でEFS・OSに有意改善 | STELLANEWS.LIFE PfizerとAstellasは、シスプラチン不適格の筋層浸潤性膀胱がん（MIBC）を対象に、パドセブ（エンホルツマブ ベドチン）＋キイトルーダ（ペムブロリズマブ）の周術期併用療法がFDAにより承認されたと発表。第3相EV-303試験でEFSとOSの改善が認められた。

FDA Approves PADCEV + Keytruda for Perioperative Treatment of Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

🔗 Full article: stellanews.life/technology_c...

#FDA #PADCEV #Keytruda #BladderCancer #Immunotherapy #ADC #EV303 #Astellas #Pfizer #Oncology

【FDA、パドセブ＋キイトルーダ併用療法を承認】
米国FDAは、筋層浸潤性膀胱がん（MIBC）に対して、
エンホルツマブ ベドチン（パドセブ）＋ペムブロリズマブ（キイトルーダ）の
周術期併用療法を承認しました。
💡 第3相EV-303（KEYNOTE-905）試験では、
・イベントフリー生存（EFS）リスクを約60％低減
・全生存（OS）リスクを約50％低減
と、有意な改善を示しました。

#FDA承認 #膀胱がん #パドセブ #キイトルーダ #EV303試験 #ADC #免疫療法 #がん治療 #Astellas #Pfizer

China’s NMPA Approves Zolbetuximab for Injection

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#Zolbetuximab
#Wiluyi
#CLDN182
#GastricCancer
#GEJCancer
#Astellas
#NMPAApproval
#Oncology
#TargetedTherapy
#MonoclonalAntibody

Pharma has varying levels of success developing drugs. That's a boon for biotech

Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022

$AMGN, $NVO, #Eisai top the list
$GSK, #Astellas, $ABBV are at the bottom

#learnbiotechinvesting #BiotechPrometheus

"Significant shift" as NICE widens prostate cancer drug use NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market

#menshealth #NICE #prostatecancer #hormonesensitiveprostatecancer #HSPC #abiraterone #JnJ #Zytiga #brandedpharmaceuticals #NICEguidance #advancedHSPC #androgendeprivationtherapy #ADT #Bayer #Nubeqa #Astellas #Xtandi #Erleada #genericmedicines #ProstateCancerUK
zurl.co/fzdbT

Fezolinetant shows real-world promise for menopause symptoms - PharmaTimes Preliminary phase 4 data highlights improvements in sleep, work productivity and quality of life

#womenshealth #Fezolinetant #menopausesymptoms #phase4data #AstellasPharma #Astellas #OPTIONVMSobservationalstudy #vasomotorsymptoms #VMS #menopause #menopausalVMS #Hotflashes #nightsweats #TheMenopauseSociety #sleepoutcomes #PROMISSDSF8b #actigraphyendpoints
pharmatimes.com/news/fezolin...

Astellas suffers pancreatic cancer failure with Vyloy Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.

#Astellas #pancreaticcancer #Vyloy #zolbetuximab #claudin182targetingcancerdrug #GLEAMstudy #metastaticpancreaticadenocarcinoma #GLEAMtrial #pancreaticcancerresearch #claudin182targetedtherapy #CLDN182testing #GanymedPharma #ESMO #GEJcancer #biopharma
zurl.co/DtTYd

Astellas Pharma Showcases VEOZAH Data at 2025 Menopause Society Meeting Astellas Pharma is set to present significant real-world data for VEOZAH (fezolinetant), a groundbreaking treatment for menopausal symptoms, at the 2025 Annual Meeting of The Menopause Society.

Astellas Pharma Showcases VEOZAH Data at 2025 Menopause Society Meeting #Japan #Tokyo #Astellas #Menopause #VEOZAH

A year ago, #Astellas was celebrating the first-in-class approval of its #claudin 18.2-targeting cancer drug Vyloy for gastric cancers. Now, a bid to expand its label into #pancreaticcancer has hit the buffers.

pharmaphorum.com/news/astella...

Biopharmaceutical Executives Advance Life Sciences at Veeva Commercial Summit in Europe The Veeva Commercial Summit Europe features industry leaders discussing innovations that will shape the future of biopharma and healthcare.

Biopharmaceutical Executives Advance Life Sciences at Veeva Commercial Summit in Europe #Spain #Madrid #Biopharma #Astellas #Veeva_Summit

Biopharma Leaders Unite to Shape the Future of Life Sciences at Veeva Commercial Summit in Europe The Veeva Commercial Summit in Madrid will gather over 1,200 life sciences leaders to share innovations and strategies that enhance the industry's future.

Biopharma Leaders Unite to Shape the Future of Life Sciences at Veeva Commercial Summit in Europe #Spain #Madrid #Veeva_Systems #Astellas #Bayer_AG

Astellas to Showcase Promising Findings on IZERVAY™ at AAO 2025 Annual Meeting Astellas Pharma is set to present new insights on IZERVAY™, addressing geographic atrophy at the AAO 2025 Annual Meeting, emphasizing innovation in ophthalmology.

Astellas to Showcase Promising Findings on IZERVAY™ at AAO 2025 Annual Meeting #Japan #Tokyo #Astellas #IZERVAY #Geographic_Atrophy

Orphan Drugs: Ihr Mehrwert für die Patient:innen - Pharma Fakten Welchen Nutzen haben Orphan Drugs wirklich? Wie misst man ihn – und was darf das kosten? Teil 2 des Interviews mit zwei Experten des Pharmaunternehmens Astellas.

Welchen Nutzen haben #OrphanDrugs wirklich? Wie misst man ihn – und was darf das kosten? Teil 2 des Interviews mit zwei #Experten des Pharmaunternehmens #Astellas.

pharma-fakten.de/news/orphan-...

That’s a wrap of the @anzuptrials.bsky.social #APCCC APAC Satellite Conference. Many thanks to Convenors @profiand.bsky.social #RenuEapen #EdmundChiong & #DeclanMurphy. Also thanks to our sponsors - Gold: #Bayer #Johnson&Johnson @novartis.bsky.social, Supporters: #Astellas #Pfizer #APCCCinAPAC25

Padcev/Keytruda extends survival in early bladder cancer Astellas and Pfizer plan to file Padcev for earlier-stage bladder cancer after showing a survival benefit in a combination regimen with Keytruda.

#Pfizer and #Astellas reckon they have new data for Padcev in #bladdercancer that could extend its use into earlier-stage disease, and help the drug meet lofty sales projections.

Congrats @anzuptrials.bsky.social #ENZAp @thelancetoncol.bsky.social‬ publication by Prof Emmett @ascocancer.bsky.social #Movember #CancerAustralia #Astellas #ARTnet #StVincentsClinic #RoyMorgan #Novartis #MimSoftware #GenesisCare #ANSTO #NHMRCCTC @profiand.bsky.social
anzup.org.au/wp-content/u...

Bayer bags first world approval for hot flush therapy Bayer has its first regulatory approval for non-hormonal menopause treatment elinzanetant – in the UK – as it chases down a rival drug from Astellas

NEWS: #Bayer has its first regulatory approval for non-hormonal menopause treatment elinzanetant – in the UK – as it chases down a rival drug from #Astellas.

pharmaphorum.com/news/bayer-b...

Nikon and Astellas Join Forces to Enhance Research at SakuLab in Cambridge MA Nikon Instruments and Astellas have partnered to provide advanced imaging solutions to SakuLab resident companies, fostering innovation in life sciences.

Nikon and Astellas Join Forces to Enhance Research at SakuLab in Cambridge MA #USA #Cambridge #Astellas #Nikon_Instruments #SakuLab

Astellas Pharmaceuticals Selects Veeva Vault CRM as Global Standard to Enhance Business Agility Astellas Pharmaceuticals has selected Veeva Vault CRM as its global standard solution, aiming to enhance its business agility and execution across markets.

Astellas Pharmaceuticals Selects Veeva Vault CRM as Global Standard to Enhance Business Agility #United_States #Pleasanton #Astellas #Vault_CRM #Veeva